RYTMRhythm Pharmaceuticals, Inc.

$6B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$21M

Net Income

-$21M

EPS (Diluted)

$-0.43

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$127,000

Balance Sheet

Total Assets

$18M

Total Liabilities

$76M

Stockholders' Equity

-$57M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$21M	-$18M	-18.2%
Net Income	-$21M	-$18M	-18.2%

RYTM FY 2013 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena